C2D
MCID: CMP028
MIFTS: 47

Complement Component 2 Deficiency (C2D)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Complement Component 2 Deficiency

MalaCards integrated aliases for Complement Component 2 Deficiency:

Name: Complement Component 2 Deficiency 58 12 77 54 26 76 30 6 15 41 74
C2 Deficiency 58 26 76 13
C2d 58 26 76
Complement 2 Deficiency 26 74
Complement Component-2 13

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
complement component 2 deficiency:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0060295
OMIM 58 217000
MeSH 45 D007105
ICD10 34 D84.1
MedGen 43 C3150275

Summaries for Complement Component 2 Deficiency

Genetics Home Reference : 26 Complement component 2 deficiency is a disorder that causes the immune system to malfunction, resulting in a form of immunodeficiency. Immunodeficiencies are conditions in which the immune system is not able to protect the body effectively from foreign invaders such as bacteria and viruses. People with complement component 2 deficiency have a significantly increased risk of recurrent bacterial infections, specifically of the lungs (pneumonia), the membrane covering the brain and spinal cord (meningitis), and the blood (sepsis), which may be life-threatening. These infections most commonly occur in infancy and childhood and become less frequent in adolescence and adulthood.

MalaCards based summary : Complement Component 2 Deficiency, also known as c2 deficiency, is related to apolipoprotein c-ii deficiency and lupus erythematosus. An important gene associated with Complement Component 2 Deficiency is C2 (Complement C2), and among its related pathways/superpathways are Creation of C4 and C2 activators and Complement and coagulation cascades. The drugs Exemestane and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and brain, and related phenotypes are purpura and systemic lupus erythematosus

Disease Ontology : 12 A complement deficiency that is characterized by recurrent bacterial infections, has material basis in autosomal recessive inheritance of mutation in the C2 gene.

NIH Rare Diseases : 54 Complement component 2 deficiency (C2D) is a genetic condition that affects the immune system. Signs and symptoms include recurrent bacterial infections and risk for a variety of autoimmune conditions. Infections can be very serious and are common in early life. They become less frequent during the teen and adult years. The most frequent autoimmune conditions associated with C2D are lupus (10-20%) and vasculitis. C2D is caused by mutations in the C2 gene and is inherited in an autosomal recessive fashion.

UniProtKB/Swiss-Prot : 76 Complement component 2 deficiency: A rare defect of the complement classical pathway associated with the development of autoimmune disorders, mainly systemic lupus erythematosus. Skin and joint manifestations are common and renal disease is relatively rare. Patients with complement component 2 deficiency are also reported to have recurrent invasive infections.

Wikipedia : 77 Complement C2 is a protein that in humans is encoded by the C2 gene. The protein encoded by this gene is... more...

Description from OMIM: 217000

Related Diseases for Complement Component 2 Deficiency

Diseases related to Complement Component 2 Deficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 27)
# Related Disease Score Top Affiliating Genes
1 apolipoprotein c-ii deficiency 11.4
2 lupus erythematosus 10.5
3 systemic lupus erythematosus 10.4
4 vasculitis 10.2
5 cutaneous lupus erythematosus 10.0
6 discoid lupus erythematosus 10.0
7 arthritis 10.0
8 glomerulonephritis 10.0
9 subacute cutaneous lupus erythematosus 10.0
10 multiple sclerosis 9.8
11 enterocolitis 9.8
12 myasthenia gravis 9.8
13 rheumatic fever-related antigen 9.8
14 common variable immunodeficiency 9.8
15 dermatomyositis 9.8
16 bacterial infectious disease 9.8
17 urticaria 9.8
18 angioedema 9.8
19 rheumatic disease 9.8
20 rheumatic fever 9.8
21 pericarditis 9.8
22 dermatitis 9.8
23 hemophilia 9.8
24 cold urticaria 9.8
25 myasthenia gravis congenital 9.8
26 macular degeneration, age-related, 14 9.6 C2 CFB
27 retinal drusen 9.4 C2 CFB

Graphical network of the top 20 diseases related to Complement Component 2 Deficiency:



Diseases related to Complement Component 2 Deficiency

Symptoms & Phenotypes for Complement Component 2 Deficiency

Human phenotypes related to Complement Component 2 Deficiency:

33
# Description HPO Frequency HPO Source Accession
1 purpura 33 HP:0000979
2 systemic lupus erythematosus 33 HP:0002725

Symptoms via clinical synopsis from OMIM:

58
Immunology:
systemic lupus erythematosus
autoimmune disease
sjogren syndrome
c2 deficiency

Muscle Soft Tissue:
polymyositis

Skin Nails Hair Skin:
henoch-schonlein purpura

Clinical features from OMIM:

217000

Drugs & Therapeutics for Complement Component 2 Deficiency

Drugs for Complement Component 2 Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Exemestane Approved, Investigational Phase 3,Phase 1 107868-30-4 60198
2
Letrozole Approved, Investigational Phase 3,Phase 2 112809-51-5 3902
3
Fulvestrant Approved, Investigational Phase 3,Phase 2 129453-61-8 104741 17756771
4
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
5
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
6
Simvastatin Approved Phase 2 79902-63-9 54454
7
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
8
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
9
Carboplatin Approved Phase 2,Phase 1 41575-94-4 38904 10339178 498142
10
Gemcitabine Approved Phase 2 95058-81-4 60750
11
Cisplatin Approved Phase 2,Phase 1 15663-27-1 441203 84093 2767
12
Trametinib Approved Phase 2 871700-17-3 11707110
13
ofatumumab Approved Phase 2 679818-59-8 6918251
14
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
15
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
16
Ceritinib Approved Phase 2,Phase 1 1032900-25-6
17
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
18
Palbociclib Approved, Investigational Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
19
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
20
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
21
Hydroxychloroquine Approved Phase 2 118-42-3 3652
22
Colestipol Approved Phase 2 26658-42-4
23
Loperamide Approved Phase 2 53179-11-6 3955
24
Budesonide Approved Phase 2 51333-22-3 63006 5281004
25
Radium Ra 223 dichloride Approved, Investigational Phase 1, Phase 2 444811-40-9
26
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
27
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
28
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
29
Goserelin Approved Phase 2 65807-02-5 5311128 47725
30
Sodium Citrate Approved, Investigational Phase 2 68-04-2
31
Heparin Approved, Investigational Phase 2 9005-49-6 772 46507594
32
Durvalumab Approved, Investigational Phase 2 1428935-60-7
33
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
35
Entinostat Investigational Phase 1, Phase 2,Phase 2 209783-80-2
36
Tremelimumab Investigational Phase 2 745013-59-6
37 Anticholesteremic Agents Phase 2
38 Topoisomerase Inhibitors Phase 2,Phase 1
39 topoisomerase I inhibitors Phase 2
40 Lipid Regulating Agents Phase 2
41 Hypolipidemic Agents Phase 2
42 Antimetabolites Phase 2,Phase 1
43 Antineoplastic Agents, Immunological Phase 2,Phase 1
44 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
45 Protein Kinase Inhibitors Phase 2,Phase 1
46 Immunoglobulins Phase 2,Phase 1
47 Antineoplastic Agents, Alkylating Phase 2,Phase 1
48 Antibodies, Monoclonal Phase 2,Phase 1
49 Nitrogen Mustard Compounds Phase 2
50 Immunoglobulin G Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Recruiting NCT03778931 Phase 3 Elacestrant;Standard of Care
2 Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) Completed NCT01281761 Phase 2 cetuximab/irinotecan/simvastatin
3 Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag Completed NCT01147809 Phase 2 Eltrombopag olamine
4 Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias Completed NCT00920140 Phase 2 GSK1120212;GSK1120212
5 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed NCT01520922 Phase 2 Bendamustine
6 Study Of Ispinesib In Subjects With Breast Cancer Completed NCT00089973 Phase 2 Ispinesib
7 A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting NCT02957019 Phase 1, Phase 2 L19-IL2 - Ph I;L19-IL2 at RD - Ph II;Rituximab
8 Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1 Recruiting NCT03007719 Phase 2 Fluorine F 18 Ara-G
9 Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer Recruiting NCT03037437 Phase 2 Sorafenib (SOR);Hydroxychloroquine (HCQ)
10 A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma Recruiting NCT03215030 Phase 1, Phase 2 TAK-573
11 A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide Recruiting NCT02400476 Phase 2 Neratinib;Loperamide;Colestipol;Budesonide
12 A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges Recruiting NCT02336451 Phase 2 LDK378
13 Docetaxel With or Without AZD6244 in Melanoma Active, not recruiting NCT01256359 Phase 2 Docetaxel and AZD6244;Docetaxel and placebo
14 Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) Active, not recruiting NCT02880943 Phase 1, Phase 2 XOFIGO
15 A Study of Abemaciclib in Recurrent Glioblastoma Active, not recruiting NCT02981940 Phase 2 Abemaciclib
16 Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer Active, not recruiting NCT02437136 Phase 1, Phase 2 entinostat;pembrolizumab
17 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Active, not recruiting NCT02953652 Phase 2 HBI-8000
18 Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Active, not recruiting NCT03007979 Phase 2 Palbociclib;Letrozole;Fulvestrant;Goserelin
19 Regional Anticoagulation of Dialysis Circuits With a Calcium-free Citrate-containing Dialysate Not yet recruiting NCT03842657 Phase 2
20 PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma Not yet recruiting NCT03598816 Phase 2 Durvalumab;Tremelimumab
21 Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance Not yet recruiting NCT03833440 Phase 2 Durvalumab (MEDI4736);Monalizumab (IPH2201;Oleclumab (MEDI9447);AZD6738;DOCETAXEL
22 Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer Withdrawn NCT02115594 Phase 2 Fulvestrant;Entinostat;Placebo
23 Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer Completed NCT01594398 Phase 1 entinostat;entinostat;Erlotinib;Erlotinib;Exemestane;Exemestane
24 A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients Completed NCT00927823 Phase 1 PF-04691502
25 Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers Completed NCT02325713 Phase 1 Oral dispersible tablet of praziquantel (ODT-PZQ);Cysticide;ODT-PZQ;ODT-PZQ;ODT-PZQ;Cysticide
26 Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Completed NCT01351935 Phase 1 AVL-292
27 A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase Completed NCT01283516 Phase 1 LDK378
28 A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer Completed NCT00141297 Phase 1 PD-0332991
29 A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer Completed NCT01121575 Phase 1 PF-02341066;PF-00299804;PF-02341066;PF-00299804
30 A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer Completed NCT00927589 Phase 1 carboplatin;docetaxel;trastuzumab
31 Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer Completed NCT00291577 Phase 1 Sunitinib (Sutent);Taxotere
32 Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer Recruiting NCT03737370 Phase 1 Docetaxel
33 Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome Recruiting NCT03113695 Phase 1 Obinutuzumab;lenalidomide;HDMP
34 A Study of MORAb-202 in Participants With Solid Tumors Recruiting NCT03386942 Phase 1 MORAb-202
35 Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma Recruiting NCT03422094 Phase 1
36 First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors Recruiting NCT02977195 Phase 1 NP137
37 Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma Recruiting NCT03121677 Phase 1 Poly ICLC
38 Eribulin Mesylate and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery Recruiting NCT03361436 Phase 1 Eribulin Mesylate
39 Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia Recruiting NCT03467386 Phase 1 Cyclophosphamide;Tacrolimus
40 Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer Recruiting NCT02848443 Phase 1 Trifluridine/tipiracil hydrochloride (S 95005);Oxaliplatin;Bevacizumab;Nivolumab
41 Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. Not yet recruiting NCT03784040 Phase 1 OTSGC-A24;Nivolumab;Ipilimumab
42 Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Suspended NCT02117336 Phase 1 P1446A-05
43 Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Terminated NCT02138812 Phase 1 BAY1161909;Paclitaxel
44 Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) Terminated NCT03116971 Phase 1 M3814;Cisplatin;Etoposide
45 A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC Terminated NCT02346370 Phase 1 PEGylated recombinant human hyaluronidase PH20;Docetaxel
46 Biomarkers of Meats and Potatoes Intake. Completed NCT03305718 Not Applicable
47 Minimal Residual Disease in Peripheral T-cell Lymphoma Recruiting NCT03297697
48 CryoBalloon Ablation for Treatment of Duodenal Adenomas Not yet recruiting NCT03847636 Not Applicable
49 Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer Not yet recruiting NCT03846128

Search NIH Clinical Center for Complement Component 2 Deficiency

Genetic Tests for Complement Component 2 Deficiency

Genetic tests related to Complement Component 2 Deficiency:

# Genetic test Affiliating Genes
1 Complement Component 2 Deficiency 30 C2

Anatomical Context for Complement Component 2 Deficiency

MalaCards organs/tissues related to Complement Component 2 Deficiency:

42
Lung, Breast, Brain, Skin, Spinal Cord, T Cells, Bone

Publications for Complement Component 2 Deficiency

Articles related to Complement Component 2 Deficiency:

(show top 50) (show all 90)
# Title Authors Year
1
Hereditary Heterozygous C2 Deficiency: Variable Clinical and Serological Manifestations Among Three Sisters. ( 27502238 )
2017
2
Gonococcal Arthritis and C2 Deficiency. ( 29102589 )
2017
3
Niemann-Pick type C2 deficiency impairs autophagy-lysosomal activity, mitochondrial function, and TLR signaling in adipocytes. ( 27402802 )
2016
4
Supraglottitis due to group B streptococcus in an adult with IgG4 and C2 deficiency: a case report and review of the literature. ( 25124395 )
2015
5
Niemann-pick type C2 deficiency in human fibroblasts confers robust and selective activation of prostaglandin E2 biosynthesis. ( 23814065 )
2013
6
Overcoming C2 deficiency. ( 22863655 )
2012
7
Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation. ( 22842196 )
2012
8
Complement C2 deficiency disarranging innate and adaptive humoral immune responses in a pediatric patient: treatment with rituximab. ( 20890976 )
2011
9
Impaired opsonization with complement and phagocytosis of Streptococcus pyogenes in sera from subjects with inherited C2 deficiency. ( 20417301 )
2010
10
Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. ( 20727163 )
2010
11
Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. ( 17478473 )
2007
12
C2 deficiency primary meningococcal arthritis of the elbow by Neisseria meningitidis serogroup Y in a 12-year old girl. ( 17653506 )
2007
13
Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. ( 16785571 )
2006
14
Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. ( 15643297 )
2005
15
Anti-tumor necrosis factor therapy is tolerated in an individual with homozygous complement C2 deficiency. ( 16357744 )
2005
16
Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency. ( 12959222 )
2003
17
Necrotic facial papules in an adolescent: C2 deficiency with eventual development of lupus erythematosus. ( 12869153 )
2003
18
Impaired IgG responses in a child with homozygous C2 deficiency and recurrent pneumococcal septicaemia. ( 11227345 )
2001
19
Binding of immune complexes to erythrocyte CR1 (CD35): difference in requirement of classical pathway components and indication of alternative pathway-mediated binding in C2-deficiency. ( 10886790 )
2000
20
Low concentrations of immunoglobulin G antibodies to Salmonella serogroup C in C2 deficiency: suggestion of a mannan-binding lectin pathway-dependent mechanism. ( 10607303 )
1999
21
A novel type II complement C2 deficiency allele in an African- American family. ( 9670930 )
1998
22
HLA-Cw alleles associated with HLA extended haplotypes and C2 deficiency. ( 9802610 )
1998
23
C2 deficiency in blood donors and lupus patients: prevalence, clinical characteristics and HLA-associations in the Brazilian population. ( 9229366 )
1997
24
Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189 --> Phe; Gly444 --> Arg) cause impaired C2 secretion. ( 8621452 )
1996
25
Multifocal stenosing ulcerations of the small intestine revealing vasculitis associated with C2 deficiency. ( 8613071 )
1996
26
Homozygous C2 deficiency: association with defective alternative pathway function and immunoglobulin deficiency. ( 8645999 )
1996
27
Serum concentrations of C4 isotypes and factor B in type I C2 deficiency suggest haplotype-dependent quantitative expression of MHC class III complement genes. ( 7576717 )
1995
28
Recurrent infections, pericarditis and renal disease in a patient with total C2 deficiency and decreased NK cell function consistent with acute rheumatic fever and systemic lupus erythematosus. ( 8203960 )
1994
29
Prevalence of a mutation causing C2 deficiency in systemic lupus erythematosus. ( 7932427 )
1994
30
Type I human complement C2 deficiency. A 28-base pair gene deletion causes skipping of exon 6 during RNA splicing. ( 8420996 )
1993
31
Characterization of type I complement C2 deficiency MHC haplotypes. Strong conservation of the complotype/HLA-B-region and absence of disease association due to linked class II genes. ( 7901282 )
1993
32
Prevalence of the type I complement C2 deficiency gene in Swedish systemic lupus erythematosus patients. ( 8305927 )
1993
33
Type I human complement C2 deficiency. A 28-base pair gene deletion causes skipping of exon 6 during RNA splicing. ( 1577763 )
1992
34
Molecular heterogeneity of C2 deficiency. ( 1542325 )
1992
35
A restriction fragment of the C2 gene is a unique marker for C2 deficiency and the uncommon C2 allele C2*B (a marker for type 1 diabetes). ( 1684365 )
1991
36
Defective activation of the alternative pathway of complement in patients with homozygous C2 deficiency: studies in two unrelated families. ( 1915518 )
1991
37
Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency. ( 2290166 )
1990
38
Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus. ( 2300790 )
1990
39
Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. ( 2751722 )
1989
40
Combined homozygous factor H and heterozygous C2 deficiency in an Italian family. ( 2966809 )
1988
41
Subacute cutaneous lupus erythematosus in multiple members of a family with C2 deficiency. ( 3467658 )
1987
42
Vasculitis simulating eczematous dermatitis due to C2 deficiency. ( 2442945 )
1987
43
Desensitization to factor VIII in a patient with classic hemophilia and C2 deficiency. ( 3103496 )
1987
44
Deficiency of C2, the second complement component, in the family of a patient with SLE-like syndrome: the first case of hereditary C2 deficiency in Czechoslovakia. ( 3428724 )
1987
45
C2 deficiency, moderately low IgG2 concentrations and lack of the G2m(23) allotype marker in a child with repeated bacterial infections. ( 3604675 )
1987
46
HLA genotypes in a family with a case of homozygous C2 deficiency and discoid lupus erythematosus. ( 2431580 )
1986
47
Heterozygous C2 deficiency associated with angioedema, myasthenia gravis, and systemic lupus erythematosus. ( 3718019 )
1986
48
Sex influences transmission of the supratype associated with the C2 deficiency allele: a possible mechanism for the maintenance of heterozygosity and disease susceptibility. ( 3980253 )
1985
49
Enhancement of granulocyte oxidative metabolism in sera from patients with C2 deficiency and systemic lupus erythematosus. ( 6307890 )
1983
50
C2 deficiency vasculitis: complication of enterocolitis, cutaneous ulcers, and neuropsychiatric disorder. ( 6295137 )
1983

Variations for Complement Component 2 Deficiency

UniProtKB/Swiss-Prot genetic disease variations for Complement Component 2 Deficiency:

76
# Symbol AA change Variation ID SNP ID
1 C2 p.Cys131Tyr VAR_008544 rs760744400
2 C2 p.Ser209Phe VAR_008545 rs28934590
3 C2 p.Gly464Arg VAR_008546 rs151340617

ClinVar genetic disease variations for Complement Component 2 Deficiency:

6 (show top 50) (show all 88)
# Gene Variation Type Significance SNP ID Assembly Location
1 C2 NM_000063.5(C2): c.954G> C (p.Glu318Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs9332739 GRCh37 Chromosome 6, 31903804: 31903804
2 C2 NM_000063.5(C2): c.954G> C (p.Glu318Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs9332739 GRCh38 Chromosome 6, 31936027: 31936027
3 C2; CFB NM_001710.5(CFB): c.95G> A (p.Arg32Gln) single nucleotide variant protective rs641153 GRCh37 Chromosome 6, 31914180: 31914180
4 C2; CFB NM_001710.5(CFB): c.95G> A (p.Arg32Gln) single nucleotide variant protective rs641153 GRCh38 Chromosome 6, 31946403: 31946403
5 C2; CFB NM_001710.5(CFB): c.94C> T (p.Arg32Trp) single nucleotide variant Benign rs12614 GRCh37 Chromosome 6, 31914179: 31914179
6 C2; CFB NM_001710.5(CFB): c.94C> T (p.Arg32Trp) single nucleotide variant Benign rs12614 GRCh38 Chromosome 6, 31946402: 31946402
7 C2; CFB NM_001710.5(CFB): c.26T> A (p.Leu9His) single nucleotide variant Conflicting interpretations of pathogenicity rs4151667 GRCh37 Chromosome 6, 31914024: 31914024
8 C2; CFB NM_001710.5(CFB): c.26T> A (p.Leu9His) single nucleotide variant Conflicting interpretations of pathogenicity rs4151667 GRCh38 Chromosome 6, 31946247: 31946247
9 C2 NM_001282459.1(C2): c.841_868del28 (p.Val281Profs) deletion Likely pathogenic rs9332736 GRCh37 Chromosome 6, 31902068: 31902095
10 C2 NM_001282459.1(C2): c.841_868del28 (p.Val281Profs) deletion Likely pathogenic rs9332736 GRCh38 Chromosome 6, 31934291: 31934318
11 C2; CFB NM_001710.5(CFB): c.1598A> G (p.Lys533Arg) single nucleotide variant Benign/Likely benign rs149101394 GRCh37 Chromosome 6, 31918154: 31918154
12 C2; CFB NM_001710.5(CFB): c.1598A> G (p.Lys533Arg) single nucleotide variant Benign/Likely benign rs149101394 GRCh38 Chromosome 6, 31950377: 31950377
13 C2 NM_000063.5(C2): c.-145A> C single nucleotide variant Likely benign rs150299426 GRCh38 Chromosome 6, 31927608: 31927608
14 C2 NM_000063.5(C2): c.-145A> C single nucleotide variant Likely benign rs150299426 GRCh37 Chromosome 6, 31895385: 31895385
15 C2 NM_000063.5(C2): c.81C> T (p.Asn27=) single nucleotide variant Uncertain significance rs201336507 GRCh38 Chromosome 6, 31927989: 31927989
16 C2 NM_000063.5(C2): c.81C> T (p.Asn27=) single nucleotide variant Uncertain significance rs201336507 GRCh37 Chromosome 6, 31895766: 31895766
17 C2 NM_000063.5(C2): c.218C> T (p.Pro73Leu) single nucleotide variant Likely benign rs137902889 GRCh38 Chromosome 6, 31928126: 31928126
18 C2 NM_000063.5(C2): c.218C> T (p.Pro73Leu) single nucleotide variant Likely benign rs137902889 GRCh37 Chromosome 6, 31895903: 31895903
19 C2; CFB NM_000063.5(C2): c.1414G> A (p.Ala472Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs142243595 GRCh38 Chromosome 6, 31943278: 31943278
20 C2; CFB NM_000063.5(C2): c.1414G> A (p.Ala472Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs142243595 GRCh37 Chromosome 6, 31911055: 31911055
21 C2; CFB NM_000063.5(C2): c.1450A> G (p.Ile484Val) single nucleotide variant Conflicting interpretations of pathogenicity rs145988012 GRCh38 Chromosome 6, 31943314: 31943314
22 C2; CFB NM_000063.5(C2): c.1450A> G (p.Ile484Val) single nucleotide variant Conflicting interpretations of pathogenicity rs145988012 GRCh37 Chromosome 6, 31911091: 31911091
23 C2; CFB NM_000063.5(C2): c.1835G> A (p.Ser612Asn) single nucleotide variant Likely benign rs573509224 GRCh38 Chromosome 6, 31944159: 31944159
24 C2; CFB NM_000063.5(C2): c.1835G> A (p.Ser612Asn) single nucleotide variant Likely benign rs573509224 GRCh37 Chromosome 6, 31911936: 31911936
25 C2 NM_000063.5(C2): c.*120T> C single nucleotide variant Uncertain significance rs886061294 GRCh38 Chromosome 6, 31945477: 31945477
26 C2 NM_000063.5(C2): c.*120T> C single nucleotide variant Uncertain significance rs886061294 GRCh37 Chromosome 6, 31913254: 31913254
27 C2; CFB NM_000063.5(C2): c.*304A> G single nucleotide variant Conflicting interpretations of pathogenicity rs72842444 GRCh38 Chromosome 6, 31945661: 31945661
28 C2; CFB NM_000063.5(C2): c.*304A> G single nucleotide variant Conflicting interpretations of pathogenicity rs72842444 GRCh37 Chromosome 6, 31913438: 31913438
29 C2; CFB NM_001710.5(CFB): c.221G> A (p.Arg74His) single nucleotide variant Likely benign rs117314762 GRCh38 Chromosome 6, 31946529: 31946529
30 C2; CFB NM_001710.5(CFB): c.221G> A (p.Arg74His) single nucleotide variant Likely benign rs117314762 GRCh37 Chromosome 6, 31914306: 31914306
31 C2; CFB NM_001710.5(CFB): c.405C> T (p.Tyr135=) single nucleotide variant Likely benign rs4151650 GRCh37 Chromosome 6, 31914890: 31914890
32 C2; CFB NM_001710.5(CFB): c.405C> T (p.Tyr135=) single nucleotide variant Likely benign rs4151650 GRCh38 Chromosome 6, 31947113: 31947113
33 C2; CFB NM_001710.5(CFB): c.600C> T (p.Ser200=) single nucleotide variant Likely benign rs113197809 GRCh37 Chromosome 6, 31915240: 31915240
34 C2; CFB NM_001710.5(CFB): c.600C> T (p.Ser200=) single nucleotide variant Likely benign rs113197809 GRCh38 Chromosome 6, 31947463: 31947463
35 C2; CFB NM_001710.5(CFB): c.754G> A (p.Gly252Ser) single nucleotide variant Likely benign rs4151651 GRCh37 Chromosome 6, 31915614: 31915614
36 C2; CFB NM_001710.5(CFB): c.754G> A (p.Gly252Ser) single nucleotide variant Likely benign rs4151651 GRCh38 Chromosome 6, 31947837: 31947837
37 C2; CFB NM_001710.5(CFB): c.858C> T (p.Phe286=) single nucleotide variant Likely benign rs117905900 GRCh37 Chromosome 6, 31915819: 31915819
38 C2; CFB NM_001710.5(CFB): c.858C> T (p.Phe286=) single nucleotide variant Likely benign rs117905900 GRCh38 Chromosome 6, 31948042: 31948042
39 C2; CFB NM_001710.5(CFB): c.1143C> T (p.Arg381=) single nucleotide variant Conflicting interpretations of pathogenicity rs150920440 GRCh37 Chromosome 6, 31916713: 31916713
40 C2; CFB NM_001710.5(CFB): c.1143C> T (p.Arg381=) single nucleotide variant Conflicting interpretations of pathogenicity rs150920440 GRCh38 Chromosome 6, 31948936: 31948936
41 C2 NM_000063.5(C2): c.1066C> T (p.Leu356Phe) single nucleotide variant Uncertain significance rs886061293 GRCh38 Chromosome 6, 31937396: 31937396
42 C2 NM_000063.5(C2): c.1066C> T (p.Leu356Phe) single nucleotide variant Uncertain significance rs886061293 GRCh37 Chromosome 6, 31905173: 31905173
43 C2 NM_000063.5(C2): c.1130-11C> T single nucleotide variant Likely benign rs117576077 GRCh38 Chromosome 6, 31939220: 31939220
44 C2 NM_000063.5(C2): c.1130-11C> T single nucleotide variant Likely benign rs117576077 GRCh37 Chromosome 6, 31906997: 31906997
45 C2; CFB NM_000063.5(C2): c.1529G> A (p.Arg510His) single nucleotide variant Conflicting interpretations of pathogenicity rs45476300 GRCh38 Chromosome 6, 31943489: 31943489
46 C2; CFB NM_000063.5(C2): c.1529G> A (p.Arg510His) single nucleotide variant Conflicting interpretations of pathogenicity rs45476300 GRCh37 Chromosome 6, 31911266: 31911266
47 C2 NM_000063.5(C2): c.1602T> C (p.Leu534=) single nucleotide variant Uncertain significance rs767886405 GRCh38 Chromosome 6, 31943678: 31943678
48 C2 NM_000063.5(C2): c.1602T> C (p.Leu534=) single nucleotide variant Uncertain significance rs767886405 GRCh37 Chromosome 6, 31911455: 31911455
49 C2 NM_000063.5(C2): c.1902+5G> A single nucleotide variant Uncertain significance rs201711512 GRCh38 Chromosome 6, 31944231: 31944231
50 C2 NM_000063.5(C2): c.1902+5G> A single nucleotide variant Uncertain significance rs201711512 GRCh37 Chromosome 6, 31912008: 31912008

Expression for Complement Component 2 Deficiency

Search GEO for disease gene expression data for Complement Component 2 Deficiency.

Pathways for Complement Component 2 Deficiency

GO Terms for Complement Component 2 Deficiency

Biological processes related to Complement Component 2 Deficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.16 C2 CFB
2 regulation of complement activation GO:0030449 8.96 C2 CFB
3 complement activation GO:0006956 8.62 C2 CFB

Molecular functions related to Complement Component 2 Deficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.16 C2 CFB
2 serine-type endopeptidase activity GO:0004252 8.96 C2 CFB
3 serine-type peptidase activity GO:0008236 8.62 C2 CFB

Sources for Complement Component 2 Deficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....